Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

This session addresses hepatitis C virus (HCV) controversies and lessons from HIV from three perspectives: science, community, and policy. A WHO-recognized major public health problem, chronic HCV disease is associated with substantial morbidity and mortality among over 80 million viremic people worldwide. It disproportionately affects people living with HIV, in particular persons with history of injection drug use. HCV complicates the management of HIV and affects the response to ART. The availability of effective HCV treatment, with high cure rates for all genotypes, offers unprecedented opportunities. However, barriers stand in the way, including high treatment costs, health services delivery issues, insufficient HCV screening programmes and limited HCV prevalence data. This session, tailored to policymakers, patient advocates, community members, treatment activists, and funders, equips delegates with the key arguments and actions necessary to effectively address HCV treatment controversies head–on in order to improve HCV treatment access.

16:30
WEBS0101
Introduction
16:35
WEBS0102
Hepatitis C state-of-the-art
Stanislas Pol, France
Slides
16:50
WEBS0103
Lessons for policymakers from HIV for hepatitis C
Mark Heywood, South Africa
17:05
WEBS0104
Bringing down the cost of hepatitis treatment in resource-limited settings: the community perspective
Polly Clayden, United Kingdom
Slides
17:20
WEBS0105
Implementation of a sustainable Hepatitis C treatment program in Cameroon
Oudou Njoya, Cameroon
Slides
17:35
WEBS0106
Discussion
17:55
WEBS0107
Closing remarks